Abstract
In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Current Medicinal Chemistry
Title: Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Volume: 9 Issue: 13
Author(s): F. Manetti, F. Corelli, G. Strappaghetti and M. Botta
Affiliation:
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Abstract: In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Export Options
About this article
Cite this article as:
Manetti F., Corelli F., Strappaghetti G. and Botta M., Arylpiperazines with Affinity Toward a1-Adrenergic Receptors, Current Medicinal Chemistry 2002; 9 (13) . https://dx.doi.org/10.2174/0929867023369961
DOI https://dx.doi.org/10.2174/0929867023369961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm
Current Drug Targets The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Preconception Care for Diabetic Women: Background, Barriers, and Strategies for Effective Implementation
Current Diabetes Reviews Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Statins in Peripheral Arterial Disease
Current Pharmaceutical Design Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer’s Disease
Current Alzheimer Research Targeting the Endothelial Ca2+ Toolkit to Rescue Endothelial Dysfunction in Obesity Associated-Hypertension
Current Medicinal Chemistry Clinical Perspectives on the Role of Anti-Platelet and Statin Therapy in Patients with Vascular Diseases
Current Vascular Pharmacology Demonstration of the Efficacy of Statins in Resolution of Plaque Inflammation by Serial FDG Imaging
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect on Morphology, Osmotic Fragility and Electro Kinetic Potential of Erythrocytes in Hypertension
Current Hypertension Reviews PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design
Current Medicinal Chemistry